Liquid Biopsy For Cancer Diagnostics Market Competition Analysis 2025: How Players Are Shaping Growth

Liquid Biopsy For Cancer Diagnostics Global Market Report 2025

The Business Research Company's Liquid Biopsy For Cancer Diagnostics Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, December 18, 2025 /EINPresswire.com/ -- "The Liquid Biopsy For Cancer Diagnostics market is dominated by a mix of global healthcare leaders and emerging biotech innovators. Companies are investing in advanced biomarker discovery, high-sensitivity detection platforms, and data-driven clinical decision tools to enhance diagnostic accuracy and expand clinical adoption. Understanding the competitive landscape is essential for stakeholders seeking to accelerate innovation, scale commercial deployment, and gain a differentiated market position.

Which Market Player Is Leading the Liquid Biopsy For Cancer Diagnostics Market?
According to our research, F. Hoffmann-La Roche Ltd led global sales in 2023 with a 5% market share. The Diagnostics division of the company partially involved in the liquid biopsy for cancer diagnostics market provides diagnostic instruments, reagents, consumables, and test kits for use in centralized and point of care solutions, molecular diagnostics, diabetes care, tissue diagnostics and others.

How Concentrated Is the Liquid Biopsy For Cancer Diagnostics Market?
The market is fragmented, with the top 10 players accounting for 24% of total market revenue in 2023. This level of fragmentation reflects the market’s evolving state, where technological innovation, assay accuracy, clinical validation, and regulatory approval cycles act as significant barriers to scale. Large, established diagnostics and life sciences companies such as F. Hoffmann-La Roche AG, Thermo Fisher Scientific, and Illumina hold a competitive edge through broad product portfolios, integrated testing workflows, and strong clinical and research partnerships. Meanwhile, specialized firms like Guardant Health, Exact Sciences, and Natera compete by advancing high-sensitivity genomic and multi-cancer early detection platforms. As clinical adoption grows and reimbursement frameworks mature, the market is likely to see increased strategic collaborations, acquisitions, and platform consolidation, which may gradually strengthen the position of leading players while enabling niche innovators to align with larger global networks.

Leading companies include:
o F. Hoffmann-La Roche AG (5%)
o Thermo Fisher Scientific Inc (3%)
o Guardant Health Inc (3%)
o Illumina Inc (3%)
o Exact Sciences Corporation (2%)
o Natera Inc (2%)
o Johnson & Johnson Services Inc (2%)
o Bio-Rad Laboratories Inc (2%)
o Caris Life Science (1%)
o Sysmex Corporation (1%)

Request a free sample of the Liquid Biopsy For Cancer Diagnostics Market report:
https://www.thebusinessresearchcompany.com/sample_request?id=12205&type=smp

Which Companies Are Leading Across Different Regions?
North America: Twist Bioscience Corporation, Biocept, Inc, Bio Mark Diagnostics Inc, GRAIL, Inc, Foundation Medicine, Inc, Guardant Health, Inc, and Gene Centric Therapeutics, Inc are leading companies in this region.

Asia Pacific: Strand Life Sciences Private Limited, Guardant Health Japan Corporation, Adicon Holdings Limited, Thermo Fisher Scientific Inc, and Illumina Inc are leading companies in this region.

Western Europe: SOPHiA GENETICS SA, QIAGEN N.V, and Novigenix SA are leading companies in this region.
Eastern Europe: Roche Diagnostics Polska Sp. z o.o, QIAGEN N.V, Thermo Fisher Scientific Inc, and Janssen Diagnostics LLC are leading companies in this region.

South America: DGLAB Diagnósticos Laboratoriais; Oncoclínicas Group is Oncoclínicas do Brasil Serviços Médicos S.A.; and Grupo Fleury is Fleury S.A are leading companies in this region.

What Are the Major Competitive Trends in the Market?
• Next-Generation Liquid Biopsy Tool is transforming to detect and analyze biomarkers in body fluids
• Example: Twist Bioscience cfDNA (circulating cell-free deoxyribonucleic acid) Library Preparation Kit (October 2024) assigns unique circulating cell-free deoxyribonucleic acid (cfDNA) molecules, thereby improving the accuracy and sensitivity of tests for tumor variants.
• These innovations help the detection of circulating tumor deoxyribonucleic acid (ctDNA) in blood samples, offering significant advancements in cancer screening and monitoring.

Which Strategies Are Companies Adopting to Stay Ahead?
• Expanding genomic profiling panels to improve early-stage detection accuracy and multi-cancer screening capability
• Developing Artificial intelligence-driven biomarker interpretation engines to accelerate clinical decision support for oncologists
• Strengthening partnerships with oncology centres and pharma companies to validate clinical outcomes and widen adoption
• Streamlining sample-to-result workflows through automated microfluidics and cloud-integrated lab systems to improve scalability and reduce turnaround times

Access the detailed Liquid Biopsy For Cancer Diagnostics Market report here:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.